NEWS & COMMENTS

    PROHOST    FILTER

   Diabetes Is In Between Good Hands

        Pharmaceutical firms, biotech firms and academic research centers are cruising towards conquering diabetes. The pipelines of these firms contain new molecules that are marking an incredible advancement in the management of diabetes with regard to total control of blood sugar level, the prevention of side effects and the treatment of the side effects as they occur. Prohost is preparing an essay about the whole subject of diabetes, the new treatments and the firms behind them.

Eye  On

AMYLIN (AMLN)

       The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Evaluation Agency (EMEA) has issued a positive opinion recommending approval of exenatide developed by  Amylin Pharmaceuticals (AMLN) and Eli Lilly (LLY). The drug is intended for the treatment of type 2 diabetes. If approved, this new medicine is planned to be marketed throughout the European Union under the proposed brand name BYETTA®. Marketing authorization by the European Commission is expected later this year.

Amylin and Lilly are seeking approval of exenatide as an adjunctive therapy to improve blood sugar control in patients with type 2 diabetes who have not achieved adequate control on metformin and/or sulfonylurea, two common oral diabetes medications.

READ MORE: Exenatide Receives Positive Opinion From the European Committee for Medicinal Products for Human Use for the Treatment of Type 2 Diabetes

Prohost is independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients. There can be no assurance that future events relating to the profiled company will occur as anticipated. The information contained herein is provided as an information service only. Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC") and/or the National Association of Securities Dealers ("NASD"). We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at: http://www.sec.gov/consumer/cyberfr.htm